USFDA Final Approval
Alembic USFDA Approval for Prucalopride Tablets
NSE
APLLTD
BSE
533573
Alembic Pharmaceuticals Limited has received USFDA Final Approval for its Prucalopride Tablets (1 mg and 2 mg), the generic equivalent of Motegrity® by Takeda Pharmaceuticals USA Inc. The approval strengthens the company’s U.S. generics portfolio and expands its regulatory approvals in a niche gastrointestinal therapy segment.
PRICE-SENSITIVE TRIGGER
Event: Alembic USFDA Approval
Type: USFDA Final Approval
Impact: Positive
Immediate Effect: The approval enables Alembic to commercialize Prucalopride Tablets in the U.S. market, subject to commercial launch decisions, while expanding its portfolio of approved generic products.
What Happened ?
Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, 1 mg and 2 mg. The product is therapeutically equivalent to Motegrity® of Takeda Pharmaceuticals USA Inc. and is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
key details
Key Highlights
- Received USFDA Final Approval for Prucalopride Tablets (1 mg and 2 mg).
- Product is the generic equivalent of Motegrity® by Takeda Pharmaceuticals USA Inc.
- Indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
- Estimated U.S. market size is US$100 million for the twelve months ended March 2026, according to IQVIA.
- Alembic now has:
- 245 cumulative ANDA approvals
- 225 Final Approvals
- 20 Tentative Approvals
- The approval further strengthens the company’s U.S. generic pharmaceutical portfolio.
Note:
- The latest USFDA approval expands Alembic’s product pipeline in the U.S. generics market and enhances commercialization opportunities in the gastrointestinal therapeutic segment. The cumulative growth in ANDA approvals also reinforces the company’s regulatory execution capabilities and long-term expansion strategy in regulated markets.
Risk Analysis
Summary:
- Although regulatory approval has been secured, commercial performance will depend on launch timing, competitive intensity, pricing dynamics, and market penetration in the U.S. generics market.
Key Risks:
- Commercial launch timeline has not been disclosed.
- Generic pricing pressure may affect profitability.
- Market share depends on competition and customer adoption.
- Regulatory approvals do not guarantee immediate revenue generation.
- Actual sales may differ from the estimated market opportunity.
Worst Case:
- If pricing pressure intensifies or commercialization is delayed, the product may generate lower-than-expected revenue despite receiving USFDA approval.
Risk Level: Low
Company Commentary
According to Alembic Pharmaceuticals:
- The company has received USFDA Final Approval for Prucalopride Tablets, 1 mg and 2 mg.
- The product is therapeutically equivalent to Motegrity®.
- The estimated U.S. market opportunity is US$100 million.
- Alembic’s cumulative USFDA approvals have increased to 245 ANDAs, including 225 final approvals and 20 tentative approvals.
Official Exchange Filing: Alembic Pharmaceuticals Limited
